Topical Corticosteroid Abuse in Dermatology

Similar documents
Topical steroid abuse on face: a prospective study from a tertiary care centre of north India

Too Much of anything is Bad - Topical Corticosteroid Misuse on the Face

Topical steroids - fairness fervour to fallout

Topical corticosteroid abuse on face: a clinical study of 100 patients

Study of prescribing pattern of topical corticosteroids in dermatology out patients department in a Tertiary Care Hospital in Puducherry

Topical Corticosteroid Misuse: The Scenario in Patients Attending a Tertiary Care Hospital in New Delhi

PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate

International Multispecialty Journal of Health (IMJH) ISSN: [ ] [Vol-3, Issue-7, July- 2017]

Research Article. Pattern of utilization of corticosteroids in department of dermatology at a tertiary care teaching hospital

Study on Steroid Utilization Pattern in a Tertiary Care Teaching Hospital

TOPCORT Cream/Ointment (Mometasone furoate 0.1%)

RECLASSIFICATION SUBMISSION. EUMOVATE Eczema and Dermatitis Cream. (Clobetasone butyrate 0.05%) From Prescription Only Medicine

Keywords: Drug Utilization Evaluation, Corticosteroids, Eczema, Cost effectiveness, Clobetasol, Fluticasone

DATA SHEET. Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).

Elements for a Public Summary

Awareness of Risk Factors for Dermatophytoses and its impact on Quality of Life among adults in Mangalore. A Cross-sectional study

PRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION. Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.

Prescribing Information

Ultravate (halobetasol propionate) Cream, 0.05% (halobetasol propionate) Ointment, 0.05% For Dermatological Use Only. Not for Ophthalmic Use.

Misuse of topical corticosteroids: a clinical study in an Iraqi hospital M.A. Al-Dhalimi 1 and N. Aljawahiry 2

DIPROSONE OV Cream and Ointment do not contain preservatives, parabens or lanolin.

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Chemically, clobetasol propionate is 21-chloro-9-fluoro,11β,17-dihydroxy-16βmethylpregna-1,4-diene-3,20-dione

Eucrisa. Eucrisa (crisaborole) Description

Prescribing Information. Taro-Clobetasol. Taro-Clobetasol

Atopic Eczema with detail on how to apply wet wraps

The Role of Low-Potency Topical Steroids in Day-to-Day Practice

Eucrisa. Eucrisa (crisaborole) Description

50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).

Atopic Dermatitis and Topical Antipsoriatics

CLINICAL PHARMACOLOGY

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

This PDF is available for free download from a site hosted by Medknow Publications

Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis

There s comfort in the familiar

For topical use only. Not for oral, ophthalmic, or intravaginal use.

Package leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate

Pharmacologic Treatment of Atopic Dermatitis

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect Cetyl alcohol For the full list of excipients, see section 6.1.

GROUP 15 TOPICAL PREPARATIONS

See Important Reminder at the end of this policy for important regulatory and legal information.

Topical Immunomodulator Step Therapy Program

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

NOVASONE CREAM, OINTMENT AND LOTION PRODUCT INFORMATION

HYDROCORTISONE OINTMENT USP,

KEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.

ZOFLUT Cream (Fluticasone propionate)

Dupixent (dupilumab)

Elements for a Public Summary

RELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

o topical and systemic

Canesten Plus Topical Cream

Cordran Cream and Cordran Ointment Flurandrenolide, USP

BETNOVATE Betamethasone 17-valerate

Prevalence of dermatological conditions in tribal place of Timbi, Bhavnagar (Saurashtra)

Triamcinolone and vitiligo

A Prospective Study on Drug Utilization Evaluation of Corticosteroids among Out-Patients of Teaching Hospital

Revised: 03/2018. *Sections or subsections omitted from the full prescribing information are not listed.

Vitiligo is a skin depigmentation disorder

Index. Springer Nature Singapore Pte Ltd K. Lahiri (ed.), A Treatise on Topical Corticosteroids in Dermatology, DOI /

PRESCRIBING INFORMATION. ratio-topisone. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid

Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)

Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BETNOVATE - S

SUMMARY OF PRODUCT CHARACTERISTICS

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Managing and Minimizing Flare-ups in Atopic Dermatitis

Medimetriks Highlights

Drug Prescribing Pattern with Cost Analysis and Monitoring of Adverse Drug Reactions in Dermatology

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

BETNOVATE SKIN CREAM. Betamethasone Valerate Cream IP QUALITATIVE AND QUANTITATIVE COMPOSITION

Zatamil. Mometasone furoate PRODUCT INFORMATION

DERMATOP Ointment (prednicarbate ointment) 0.1% FOR DERMATOLOGIC USE ONLY. NOT FOR USE IN EYES.

15 minute eczema consultation

ULTRAPROCT OINTMENT ULTRAPROCT SUPPOSITORIES

Dermatology Syllabus for 5th Year Med Students

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE TM. Clobetasol Cream IP/ Clobetasol Ointment IP

The Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah

Tinea Incognito Incorrect Initial Diagnosis. Case Series Presentation with Emphasis on the Mycological Examination

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory FLUTIVATE SKIN CREAM. Fluticasone Cream IP

PRESCRIBING INFORMATION. Cream 0.025% Topical Corticosteroid

FULL PRESCRIBING INFORMATION

Clinical profile of skin diseases in accident and emergency department attenders

See Important Reminder at the end of this policy for important regulatory and legal information.

An Audit of Prescribing Practices in CGHS Dispensaries of Kolkata, India

EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP

Designing a Campaign On Topical steroids misuse

Antihypertensive Drugs Prescribing Pattern in Patients Attending to Medicine Outpatient Department

Dudhe et al: Rational use of medicine

Eczema & Dermatitis Clinical features: Histopathological features: Classification:

Determinants of glaucoma awareness and knowledge in patients attending ophthalmology OPD in tertiary care hospital

An Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma

Children s Hospital Of Wisconsin

PRODUCT MONOGRAPH DIPROSONE. Betamethasone Dipropionate Cream, Merck Standard, 0.05% W/W betamethasone (as dipropionate)

PRODUCT MONOGRAPH. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

PRODUCT MONOGRAPH. (Desonide Cream and Ointment) 0.05% (w/w) Glucocorticoid Royalmount Ave, Suite #100 July 29, 2014 Montreal, Quebec H4P 2T4

What s Topical About Topicals?

Transcription:

IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. IX (July. 2016), PP 110-114 www.iosrjournals.org Topical Corticosteroid Abuse in Dermatology 1 *Anup KMishra, 2 Devesh Saraswat, 1 Assistant Professor, 2 Professor, and Head Department of Dermatology, SS Medical College, Rewa, Madhya Pradesh Abstract:Topical corticosteroids are the most widely used therapeutic agents in modern dermatologic therapy. The increasing frequency of use of topical steroids has led to the detection of a number of adverse effects and is dependent upon chemical nature of the drug, the vehicle, and the location of its application. The common adverse effects on face are erythema, telangiectasia, xerosis, photosensitivity and rebound phenomenon. The improper advertisement by manufacturers, availability of steroids without prescription, improper prescribing by doctors, has resulted in the rapid emergence of topical steroid abuse. Aims and Objectives: To analyse the magnitude and adverse effects of topical steroids abuse in dermatology. Materials & Methods: This is a prospective questionnaire type study conducted in outpatient clinic of the Department of Dermatology in a tertiary hospital. A total of 200 patients of any age and of both sexes are recruited consecutively. A questionnaire eliciting demographic variables, characteristics of topical steroid use, prescription source, duration of application and adverse effects is administered to all eligible patient. Patients not consenting to answer the questionnaire or patients with co-morbidities that could cause similar changes to topical steroid side effects like Cushing s syndrome, thyroid disorders, polycystic ovaries were excluded. Statistical analysis was done using SPSS ver. 21. Results: The most common age group in which these side effects were observed is 21-30 years. Clobetasol propionate, betamethasone valerate and mometasonefuroate were the commonly used steroid by patients. It was found that 29% of patients using topical steroid were recommended by friend or pharmacist and 71% by a medical practitioner. Topical steroid abuse was seen in all 58 patients (100%) prescribed by friend or pharmacist and 58 out of 142 patients (40.84%) prescribed by medical practitioner. Tinea incognito and striae were the common side effects and were seen more commonly in non-dermatologists group. Conclusion: This study reveals that problem of topical steroid misuse is common in our country. The prevalence of side effects is significantly higher among the potent steroid users. The prevalence of side effects is significantly higher among patients of non-dermatologists (p<.05) indicating that the schedule and explanation of guidelines for correct application of steroids is a drawback among non-dermatologists. Recommendation: Education of the general public through special media programmes and the continuing medical education programme for medical and paramedical personnel are probably the most important steps that could be undertaken to reduce this problem. Keywords: Corticosteroid Abuse, Dermatology, Topical Application I. Introduction Topical corticosteroids have made a dramatic contribution to dermatology since the introduction of "compound F" or hydrocortisone in 1952 and have become the mainstay of dermatologic treatment of a wide range of inflammatory and non-infectious conditions [1]. Topical corticosteroids are today among the most commonly prescribed medications in dermatology clinics. The clinical effects are mediated by their antiinflammatory, vasoconstrictive, anti-proliferative and immunosuppressive properties [2].They are highly efficacious drugs which are used for the treatment of varied autoimmune and inflammatory dermatological conditions [2]. In India, the annual sales figure of TCs was 14 billion rupees in 2013, which accounts for almost 82% of total dermatological product sale in the country [3] Prescription of TC has become ubiquitous with dermatologists and concerns have also been raised regarding its misuse for non-labeled indications. As per the information available on the Central Drugs Standard Control Organization (CDSCO) website regarding approved dermatological indications of TC (although indications are not mentioned for all the TC molecules), its off-label use seems to be a common clinical practice in India [4,5]. However, the more serious concern is its inappropriate use in symptomatic treatment for varied dermatological disorders like acne, primary bacterial and fungal infections, undiagnosed skin rash and as fairness cream by non-registered practitioners or on the advice of pharmacist at chemist shops [6-8]. Most of these medications are sold without any prescription or patients are easily able to procure these steroid medications on a single prescription repeatedly from a local pharmacist. This leads to increased DOI: 10.9790/0853-15079110114 www.iosrjournals.org 110 Page

frequency of adverse effects and often dependence on these medications. To make the problem worse India has very few qualified dermatologists to prescribe these drugs rationally. Not only developing countries like India and Africa but even developed countries like United States of America is facing this problem. Urgent steps are therefore recommended to curb the root of this problem at the earliest. The present study was thus conducted to analyze the magnitude and adverse effects of topical steroids abuse on the body in dermatology outpatient department of a tertiary hospital and to recognize the offending topical steroids in order of frequency. II. Materials & Methods This is a prospective questionnaire type study conducted in outpatient clinic of the Department of Dermatology, SS Medical College and hospital, Rewa, MP, during the period May 2015 to May 2016. A total of 200 patients irrespective of age and sex were recruited consecutively. A questionnaire eliciting demographic variables, characteristics of topical steroid use, prescription source, duration of application and adverse effects was administered to all eligible patients. Inclusion criteria All the patients who had used topical steroid over the body for certain skin problems for more than 1 month and presented in Dermatology outpatient department are included. Wrong indication, undiagnosed dermatoses, inappropriate potency or more than 1 month use after the last consultation are criteria used to define inappropriate or unjustifiable use. Adverse effects following steroid abuse were also studied. Exclusion criteria Patients not consenting to answer the questionnaire or patients with co-morbidities that could cause similar changes to topical steroid side effects like Cushing s syndrome, thyroid disorders, polycystic ovaries were excluded. Statistical Analysis All the data was collected and entered in Microsoft excel sheet 2013 and statistical analysis was done using SPSS ver. 21.0. III. Results Mean age of study subjects was 32.3 years with slight male predominance (57%). Out of 200 patients, 108 (54%) patients were recommended topical steroid by a dermatologist while 92 (46%) by nondermatologists. Of which 10.5% and 18.5% were prescribed steroid by either a friend or a pharmacist (Table 1). Majority of the patients i.e. 57 (28.5%) had come with fungal infection followed by 21 (10.5%) cases of lichen Planus. Vitiligo, Melasma and Psoriasis were found in 14 (7%), 13 (6.5%), 13 (6.5%) cases respectively (Table 2). Adverse effects were observed in 85 (42.5%) patients out of 200. Three patients had more than one side effect. Most common side effect was tinea incognito followed by striae and telangiectasia (Table 3). Most common topical steroid used by patients was clobetasol propionate (30.5%) (Table 4). Out of 200 patients 139 (69.5%) used pure steroid cream while 61 (30.5%) used steroid cream in combination with either antifungal or antibacterial or both. Patients using cream based applications were 147 (73.5%) while 52 (26%) of them used ointment based applications. Only 1(0.5%) patient used gel preparation. Frequency of applications was twice daily in 148 (74%) patients and once a day in 52(26%) patients (Non tabulated). There were significantly higher chances of side effects in patients if the prescription is from a non-dermatologist and on application of potent steroids (p<0.05) (Table 5). IV. Discussion Topical corticosteroids were first introduced for use in 1951 and have now become the most commonly used drugs by dermatologists. Their effect in suppressing inflammatory dermatoses makes them an indispensible therapeutic tool. However, they are considered as double edged sword drugs i.e. invaluable but need careful handling by the provider and the recipient for safe and effective use [9]. Since their invention, uncontrolled use (abuse) of steroid medications has lead to many different adverse reactions. Multiple pathways including rebound vasodilatation and proinflammatory cytokine release have been proposed as the mechanism for such adverse reactions [10]. Our results clearly show that misuse of topical corticosteroids is common in our country. This is evident by number of patients who visited our department with side-effects of these drugs. Even then, adverse effects and safety of topical corticosteroids are neglected in the medical literature. The root of problem is that patients are easily able to get these topical steroid medications on a single prescription repeatedly from a local pharmacist. This leads to occurrence of sideeffects and often dependence on these medications. In our country it DOI: 10.9790/0853-15079110114 www.iosrjournals.org 111 Page

is a major problem because patients are able to procure a drug without a valid prescription from a medical practitioner. The problem is worsened when these steroid containing creams are freely advertised on television, thus it is not only a medical but also a social problem. The patient might initially start using these creams for some undiagnosed dermatoses which are often prescribed by their friends and relatives. At first the vasoconstrictive and anti-inflammatory effects of the steroids result in clearance of the primary dermatoses but on continuation of the application, they develop rashes, and on stopping the drug, there is recurrence of rashes i.e. rebound phenomenon. So, to prevent this effect, the patient resumes the use of steroid creams. The reason for consulting a doctor by most of them is when they found their skin problem no longer responds to the so called "magical effect" of the cream. Persistent use by then leads toepidermal atrophy, degeneration of dermal structure and collagen deterioration after several months. Continued or overuse of steroids can result in thinning of the skin as well as dependency on the steroid [10]. The appearance of these side effects depend on the potency of steroid, duration of use and the site of application. In present study a total of 200 patients were included. Wrong indication, undiagnosed dermatoses, inappropriate potency or more than 1 month use after the last consultation were criteria used to define inappropriate or unjustifiable use. Age range of patients in present study was from 2 years to 74 years with a mean age of 32.3 years. Out of a total of 200 patients, 114 (57%) were male and 86 (43%) were female. Eighty five of these 200 patients developed adverse effects from the use of steroids. The most common age group in which these side effects were observed is 21-30 (38.82%) years. This is probably because patients in this age group are overcautious with their appearance and with different skin conditions. Similar studies done in India show most common age for topical steroid abuse as 20-30 yearsand in Iraq it was 10-19 years [11,12]. Dermatophytic (28.5%) group of infections was the most common indication for which topical steroids were prescribed followed by lichen planus (11.5%). Vitiligo and Melasma were other common indications for which steroids were used. In other similar studies from India and Iraq, topical steroids were most commonly used as a skin lightening cream [11,12]. Adverse effects were observed in 85 (42.5%) patients. Commonest side effect which was seen in our study was Tinea incognito (19.5%) followed by striae (7%) and hypopigmentation (6.5%). Similar studies done by Saraswat et al and Al-Dhalimi et al had acne as the most common side effect as topical steroids were commonly used as a fairness cream [11,12]. Clobetasol propionate was used in 30.5% of patients while Betamethasone valerate in 28.5% of the total cases. Mometasonefuroate was the other common steroid used by patients. Betamil GM and Betnovate were the popular brand names which were used by patients. Similar study done in Iraq also showed clobetasol propionate (42.1%) as the most commonly used steroid while betamethasone valerate (26.4%) was the second most commonly used steroid [12].In another study done by Saraswat et al. betamethasonevalerate (50.1%) was the most commonly used topical steroid [11]. Most of the patients used topical steroids for a short duration of time (1-2 months) and had come to the Dermatology outpatient department because of their adverse effects. Source of prescription was studied and it was found that 29% of patients using topical steroid were recommended by friend or pharmacist and 71% by a medical practitioner. Out of these 71%, most of the prescriptions were by dermatologists (54%) followed by physician (16%) and general practitioner (1%). According to our criteria used to define inappropriate or unjustifiable use, topical steroid abuse was seen in all 58 patients (100%) prescribed by friend or pharmacist and 58 out of 142 patients (40.84%) prescribed by medical practitioner. A study done on topical steroid abuse on face by Saraswat et al showed that 59.3% of the total patients had used topical steroids on recommendation without a valid medical prescription [11]. The potency of steroids was studied and according to the classification of topical steroidsused, it was seen that although prescription by both non dermatologists and dermatologists were for products in potent group but adverse effects were more often seen in patients of non-dermatologists. This was due to lack of knowledge of potency of topical steroids by non-dermatologist group leading to their prescription in conditions in which it was either not justified or a lesser potent steroid could have been given, resulting in increased misuse and therefore adverse effects in these patients. Similar findings were observed by Al Dhalimi et al. in Iraq where potent steroids were prescribed by both the groups [12]. This study reveals that problem of topical steroid misuse is common in our country. In India free availability of these medicines has allowed many of these brands to become householdnames. Patients are unaware of risks posed by these drugs and continue to use them for long periods before seeking help from dermatologists. Improper advertisement by manufacturers, availability of steroids without prescription, improper prescribing by non-dermatologist doctors and lack of proper knowledge about these drugs has resulted in misuse of these steroid medications on a large scale [13]. DOI: 10.9790/0853-15079110114 www.iosrjournals.org 112 Page

V. Conclusion & Recommendations From our study it was concluded that topical steroid abuse is prevalent in our country. Rapidity of symptomatic relief is one of the major reasons for its misuse. The problem is worsened when patient is easily able to get these medications even without a proper prescription. In our study it was found that steroid abuse was most common in younger age group. Thus, easy availability of topical steroid, poor access ofpatients to dermatologists and lack of knowledge of the non-dermatologists make steroid abuse a common problem in India. As indicated by the data in our study, this problem is already significant and urgent steps should be taken to control this problem. Besides, it is a multiphasic problem that needs the cooperation of different sectors in the community to overcome it. Education of the general public through special media programmes and the introduction of continuing medical education programme for medical and paramedical personnel are probably the most important steps that could be undertaken to reduce this problem Bibliography [1]. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952; 19:101-2. [2]. Valencia IC, Kerdel FA. Topical glucocorticoids. In: Fitzpatrick T, editor. Dermatology in General Medicine. 5 th ed. New York: McGraw-Hill; 1999. p. 2713-7. [3]. Verma SB. Sales, status, prescriptions and regulatory problems with topical steroids in India. Indian J DermatolVenereolLeprol 2014;80:201-3. [4]. 4. Fixed Dose Combinations approved By DCG (I) since 1961 till July, 2014. Central Drugs Standard Control Organization, India. [5]. Approval Status of New Drug during 1971-1998. Central Drugs Standard Control Organization, India. Available from: http://cdsco.nic.in/ writereaddata/1971-98.doc. [Last accessed on 2015 May 28]. [6]. Saraswat A, Lahiri K, Chatterjee M, Barua S, Coondoo A, Mittal A, et al. Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients. Indian J DermatolVenereolLeprol 2011;77:160-6. [7]. Ambika H, VinodCS, Yadalla H, NithyaR, BabuAR. Topical corticosteroids abuse on face: A prospective, study on outpatients of dermatology. Our Dermatol Online 2014;5:5-8. [8]. Rathod SS, Motghare VM, Deshmukh VS, Deshpande RP, Bhamare CG, Patil JR. Prescribing practices of topical corticosteroids in the outpatient dermatology department of a rural tertiary care teaching hospital. Indian J Dermatol 2013;58:342-5. [9]. Saraswat A. Topical corticosteroid use in children: Adverse effects and how to minimise them. Indian J DermatolVenereol 2010;76:225-28. [10]. Bhat YJ, Manzoor S, Qayoom S. Steroid - induced rosacea: A clinical study of 200 patients. Indian J Dermatol, 2011;56:30-32. [11]. Saraswat A, Lahiri K, Chatterjee M, Barua S, Coondoo A, Mittal A, et al. Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients. Indian J DermatVenerolLeprol 2011;77:160-66. [12]. Al-Dhalimi MA and Aljawahiry N. Misuse of topical corticosteroids: A clinical study in an Iraqi hospital. Eastern Mediterranean Health Journal 2006;12:847-52. [13]. Lu H, Xiao T, Lu B, Dong D, Yu D, Wei H, Chen HD. Facial corticosteroid addictive dermatitis in Guiyang City, China. ClinExpDermatol 2010;35:618-21. Tables Table 1. Baseline Variables in the study group Variables Mean (SD)/ n(%) Age (years) 32.3 (5.6) Male 114 (57%) Female 86 (43%) </= 1 month use 164 (82%) > 1 month use 36 (18%) Dermatologist 108 (54%) Physician 32 (16%) General Practitioner 2(1%) Pharmacist 37 (18.5%) Friend 21 (10.5%) Table 2. Distribution based on Clinical Indication of steroid use Indication Frequency (n-200) Percent Dermatophytic Infections 57 28.5% Lichen Planus 23 11.5% Vitiligo 12 6.0% Melasma 13 6.5% Psoriasis 13 6.5% Atopic Dermatitis 10 5.0% Acne 9 4.5% Alopecia Areata 11 5.5% P. Rosea 10 5.0% P. Alba 12 6.0% Polymorphic Light eruptions 11 5.5% Others 34 17.0% DOI: 10.9790/0853-15079110114 www.iosrjournals.org 113 Page

Table 3. Distribution based on type of adverse effects Adverse Effects Frequency (n-88) Percent Tinea Incognito 39 44.3% Striae 14 15.9% Hypopigmentation 12 13.6% Telangiectasia 10 11.4% Acneform Eruptions 10 11.4% Milia 2 2.3% Perioral Dermatitis 1 1.1% Table 4. Distribution based on type of topical steroid used Drug Used Frequency (n-200) Percent Clobetasol 61 69.3% Betmethasone 57 64.8% Mometasone 28 31.8% Fluticasone 20 22.7% Fluocinolone 10 11.4% Halobetasol 8 9.1% Beclomethasone 10 11.4% Desonide 3 3.4% Others 3 3.4% Table 5. Association of Adverse events with type of prescription and potency of topical steroid used Variables Adverse Event Yes No p- value Non Dermatologist Prescription (n-92) 71 21 Dermatologist Prescription (n-108) 14 94 <0.05 Potent Steroid (n-109) 55 54 Non potentsteroid (n-91) 30 61 <0.05 DOI: 10.9790/0853-15079110114 www.iosrjournals.org 114 Page